This study evaluated potential predictors of erosions and joint space narrowing (JSN) in patients with early rheumatoid arthritis (RA). The data showed that less JSN progression was seen in postmenopausal, overweight women with RA, and smoking was associated with JSN progression.

This study investigated the possible effects of Punica granatum (pomegranate) on indicators and symptoms caused by rheumatoid arthritis (RA).

The data showed that pomegranate may have a positive impact on RA-related indicators and symptoms.

This study reviewed the effectiveness of baricitinib (Olumiant) on the progression of structural joint damage (SJD) in patients with rheumatoid arthritis (RA).

The data showed that baricitinib may significantly help slow down SJD signs found in digital imaging in patients with non-existent or insufficient response to standard treatment drugs.

This study examined the effect of sarilumab (Kevzara) compared to adalimumab (Humira) on health-related quality of life (HRQoL) based on inflammatory marker levels in patients with rheumatoid arthritis (RA). 

The data showed that sarilumab has a higher effect on improving aspects of HRQoL in patients with higher levels of inflammation in the blood.

This study investigated the relationship between the diagnosis of rheumatoid arthritis (RA) and the development of lung diseases (LDs) over five years. 

The study showed that the markers of RA activity were associated with the development of lung disease.

This trial was carried out to examine the effectiveness of switching from upadacitinib (UPA; Rinvoq) to adalimumab (ADA; Humira) and from ADA to UPA following insufficient response in patients with rheumatoid arthritis (RA). The authors found that patients who do not respond to UPA or ADA can be effectively and safely switched to the other drug.

This study investigated the effect of disease-modifying anti-rheumatic drugs (DMARDs) on cardiovascular disease (CVD) risk.

They found that abatacept (Orencia) and tumor necrosis factor inhibitors (TNFi) were associated with decreased CVD risk.

This study reviewed infection risk in patients treated with biologic and targeted disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA).

This study investigated the effect of baricitinib (Olumiant) on biomarkers in the blood, which indicate a state of joint destruction in patients with moderate to severe rheumatoid arthritis (RA).

The study showed that baricitinib reduced these biomarkers and resulted in decreased RA symptoms.

This study investigated if biological disease-modifying anti-rheumatic drugs (bDMARDs) affect diabetes risk in patients with rheumatoid arthritis (RA).

They found that bDMARD use was associated with lower rates of diabetes in these patients.